2002年缅甸全国抗结核药物耐药性调查。

National anti-tuberculosis drug resistance survey, 2002, in Myanmar.

作者信息

Ti T, Lwin T, Mar T T, Maung W, Noe P, Htun A, Kluge H H, Wright A, Aziz M A, Paramasivan C N

机构信息

National Tuberculosis Programme, Yangon General Hospital Extension Compound, Myanmar.

出版信息

Int J Tuberc Lung Dis. 2006 Oct;10(10):1111-6.

PMID:17044203

Abstract

SETTING

Thirty townships of Myanmar.

OBJECTIVES

To determine the proportions of drug-resistant tuberculosis (TB) in new and previously treated pulmonary tuberculosis (PTB) cases in Myanmar.

DESIGN

A cross-sectional study. Drug susceptibility was tested by the proportion method at the National Tuberculosis Reference Laboratory, Yangon.

RESULTS

Of 874 TB patients included from 30 sites, 849 isolates obtained from individual patients (733 from new cases and 116 from previously treated cases) were tested for susceptibility to four primary anti-tuberculosis drugs. Of 733 isolates tested from new TB patients, 10% were resistant to any one of the anti-tuberculosis drugs, 6.5% to isoniazid (INH), 4.6% to rifampicin (RMP) and 4.0% were multidrug-resistant (MDR). Of the 116 previously treated patients, 30.2% were resistant to any one of the drugs, 26.7% to INH, 15.5% to RMP and 15.5% were MDR. Previous anti-tuberculosis treatment of more than 1 month was strongly associated with the development of MDR-TB (adjusted OR 4.8, 95% CI 2.5-9.1).

CONCLUSION

The first national drug resistance survey in Myanmar revealed 4% and 15.5% MDR-TB among new and retreatment cases, respectively. Previous antituberculosis treatment was an important risk factor for MDR-TB. Continuous monitoring of drug resistance trends is needed

摘要

背景

缅甸的30个镇区。

目的

确定缅甸新诊断和既往治疗过的肺结核（PTB）病例中耐多药结核病（TB）的比例。

设计

一项横断面研究。在仰光的国家结核病参比实验室采用比例法进行药物敏感性检测。

结果

来自30个地点的874例结核病患者中，从个体患者分离得到的849株菌株（733株来自新发病例，116株来自既往治疗过的病例）接受了4种一线抗结核药物的敏感性检测。在733株新诊断结核病患者的分离菌株中，10%对任何一种抗结核药物耐药，6.5%对异烟肼（INH）耐药，4.6%对利福平（RMP）耐药，4.0%为耐多药（MDR）。在116例既往治疗过的患者中，30.2%对任何一种药物耐药，26.7%对INH耐药，15.5%对RMP耐药，15.5%为耐多药。既往抗结核治疗超过1个月与耐多药结核病的发生密切相关（校正OR 4.8，95%CI 2.5 - 9.1）。